These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24556039)

  • 1. Third-line dovitinib in metastatic renal cell carcinoma.
    Schmidinger M
    Lancet Oncol; 2014 Mar; 15(3):245-6. PubMed ID: 24556039
    [No Abstract]   [Full Text] [Related]  

  • 2. Kidney cancer: targeting FGF for third-line treatment of mRCC.
    Payton S
    Nat Rev Urol; 2014 Apr; 11(4):186. PubMed ID: 24595120
    [No Abstract]   [Full Text] [Related]  

  • 3. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
    Motzer RJ; Porta C; Vogelzang NJ; Sternberg CN; Szczylik C; Zolnierek J; Kollmannsberger C; Rha SY; Bjarnason GA; Melichar B; De Giorgi U; Grünwald V; Davis ID; Lee JL; Esteban E; Urbanowitz G; Cai C; Squires M; Marker M; Shi MM; Escudier B
    Lancet Oncol; 2014 Mar; 15(3):286-96. PubMed ID: 24556040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.
    Blesius A; Beuselinck B; Chevreau C; Ravaud A; Rolland F; Oudard S; Escudier B
    Clin Genitourin Cancer; 2013 Jun; 11(2):128-33. PubMed ID: 23332872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spontaneous regression of metastatic papillary renal cell cancer after cessation of treatment with sorafenib.
    Grenader T; Rosenbaum E; Zilber S; Bogot N; Shavit L
    Clin Genitourin Cancer; 2013 Jun; 11(2):201-3. PubMed ID: 23266054
    [No Abstract]   [Full Text] [Related]  

  • 6. New options for second-line therapy of advanced renal cancer.
    Bex A
    Lancet Oncol; 2013 May; 14(6):450-1. PubMed ID: 23598169
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.
    Angevin E; Lopez-Martin JA; Lin CC; Gschwend JE; Harzstark A; Castellano D; Soria JC; Sen P; Chang J; Shi M; Kay A; Escudier B
    Clin Cancer Res; 2013 Mar; 19(5):1257-68. PubMed ID: 23339124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urological cancer: second-line option for metastatic RCC.
    Marchesi V
    Nat Rev Clin Oncol; 2013 Jun; 10(6):305. PubMed ID: 23629471
    [No Abstract]   [Full Text] [Related]  

  • 9. Results of the first trial assessing adjuvant tyrosine kinase inhibitors in renal cell carcinoma do not reASSURE.
    Ouzaid I; Bensalah K
    Eur Urol; 2015 Sep; 68(3):542-3. PubMed ID: 26001611
    [No Abstract]   [Full Text] [Related]  

  • 10. Kidney cancer: AXIS trial data confirm axitinib as second-line option for mRCC.
    Payton S
    Nat Rev Urol; 2013 Jun; 10(6):308. PubMed ID: 23649292
    [No Abstract]   [Full Text] [Related]  

  • 11. Maturing of renal cancer therapeutics.
    Stadler WM
    J Clin Oncol; 2014 Mar; 32(8):722-4. PubMed ID: 24516015
    [No Abstract]   [Full Text] [Related]  

  • 12. Axitinib in advanced renal-cell carcinoma.
    Yousaf N; Larkin J
    Lancet Oncol; 2013 Dec; 14(13):1245-6. PubMed ID: 24206641
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of First-Line Sorafenib Treatment for Metastatic Renal Cell Carcinoma in Kidney Transplant Patients: A Single-Center Experience With Four Cases.
    Ishihara H; Kondo T; Tanabe K
    Ther Apher Dial; 2017 Aug; 21(4):414-416. PubMed ID: 28593648
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of antiangiogenic therapy.
    von Falck C; Wacker F; Rosenthal H
    J Vasc Interv Radiol; 2012 Nov; 23(11):1503. PubMed ID: 23101922
    [No Abstract]   [Full Text] [Related]  

  • 15. Sorafenib in renal cell carcinoma.
    Davoudi ET; bin-Noordin MI; Javar HA; Kadivar A; Sabeti B
    Pak J Pharm Sci; 2014 Jan; 27(1):203-8. PubMed ID: 24374450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
    Jain RK; Gandhi S; George S
    Urol Oncol; 2017 Nov; 35(11):640-646. PubMed ID: 28887097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug now immediately available in Germany].
    Aktuelle Urol; 2006 Sep; 37(5 Suppl):18-9. PubMed ID: 23646396
    [No Abstract]   [Full Text] [Related]  

  • 18. Preserving the sanctity of overall survival for drugs approved on the basis of progression-free survival: tivozanib as a case study.
    Garnick MB
    J Clin Oncol; 2013 Oct; 31(30):3746-8. PubMed ID: 24019543
    [No Abstract]   [Full Text] [Related]  

  • 19. Kidney cancer: Axitinib destined for second place?
    Payton S
    Nat Rev Urol; 2013 Dec; 10(12):678. PubMed ID: 24217676
    [No Abstract]   [Full Text] [Related]  

  • 20. Slow and steady wins the race: practical (and philosophical) considerations of treatment activity evaluation when novel anticancer agents just slow neoplastic progression.
    Porta C; Vercelli A; Paglino C
    Eur Urol; 2014 Apr; 65(4):721-2. PubMed ID: 24007714
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.